What the label lists and what reports show
Diethylpropion side effects
Diethylpropion's FDA label lists its adverse reactions in its own words. FAERS holds 127 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is chronic kidney disease (15 reports).
- Generic listed
- DEA Schedule IV
Check it at the source: the diethylpropion FDA label on DailyMed (effective December 31, 2019, Lannett Company, Inc.); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsCardiovascular: Precordial pain, arrhythmia (including ventricular), ECG changes, tachycardia, elevation of blood pressure, palpitation and rare reports of pulmonary hypertension. Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination, have been reported. Valvulopathy has been very rarely reported with diethylpropion hydrochloride tablets USP, 25 mg monotherapy, but the causal relationship remains uncertain. Central Nervous System: In a few epileptics an increase in convulsive episodes has been reported; rarely psychotic episodes at recommended doses; …
Source: FDA drug label, Lannett Company, Inc., effective December 31, 2019 (SPL set 4fdbc049-6497-4ea0-8788-d2b2963328f7), via openFDA; the full label on DailyMed
What do FAERS reports show?
127 reports list diethylpropion among the medicines taken, each a report of something that happened, not proof the medicine caused it; 5 are coded as a death and 27 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 23 reactions below, 6 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Diethylpropion: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions